X4 Pharmaceuticals, Inc.
NASDAQ:XFOR · NASDAQ Capital Market
+$0.12 today
Vol 0.21M · Avg 0.40M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:XFOR · Revenue to Net Income
Key Ratios
Analysis
$9.0M of revenue converted into -$99.7M of net income for the selected period. Gross margin is 79.2% and net margin is -1168.3%, showing how much revenue survives after costs and taxes. EPS is $-4.54, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35.1M +1273.2% | $2.6M | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $6.3M +685.1% | $797.0K | $0 | $0 -100.0% | $1.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $28.9M +1539.5% | $1.8M | $0 | $0 +100.0% | -$1.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 82.2% +13.3pp | 68.8% | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $72.2M -11.5% | $81.6M +13.4% | $72.0M +17.9% | $61.1M +25.2% | $48.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $43.5M -29.3% | $61.5M +73.3% | $35.5M +31.4% | $27.0M +9.4% | $24.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $115.7M +203.3% | $38.2M -64.5% | $107.5M +22.8% | $87.6M +19.2% | $73.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.3M +60.4% | $796.0K +90.0% | $419.0K -18.3% | $513.0K -72.9% | $1.9M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$69.0M -150.2% | -$27.6M +70.9% | -$94.9M -6.2% | -$89.3M -7.4% | -$83.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -196.5% +881.9pp | -1078.5% | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$86.9M -138.7% | -$36.4M +66.1% | -$107.5M -22.8% | -$87.6M -16.2% | -$75.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -247.4% +1176.1pp | -1423.6% | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $4.6M -20.7% | $5.8M +25.9% | $4.6M +1992.2% | $219.0K +2090.0% | $10.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $8.9M +1.2% | $8.8M +51.8% | $5.8M +44.7% | $4.0M +9.6% | $3.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $7.7M +1145.3% | -$739.0K -111.5% | $6.4M +202.6% | -$6.3M +53.0% | -$13.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$79.2M -113.1% | -$37.1M +63.3% | -$101.1M -7.7% | -$93.8M -5.8% | -$88.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -225.4% +1227.0pp | -1452.5% | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $41.0K -86.8% | $310.0K +297.4% | $78.0K +178.6% | $28.0K +64.7% | $17.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$79.2M -111.5% | -$37.5M +63.0% | -$101.2M -7.8% | -$93.9M -5.8% | -$88.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -225.6% +1239.1pp | -1464.6% | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +66.5% | -$6 +67.3% | -$17 +62.6% | -$46 +61.9% | -$120 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +66.5% | -$6 +67.3% | -$17 +62.6% | -$46 +61.9% | -$120 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $42.3M +531.0% | $6.7M +13.1% | $5.9M +179.9% | $2.1M +146.7% | $858.3K | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $42.3M +531.0% | $6.7M +13.1% | $5.9M +179.9% | $2.1M +146.7% | $858.3K | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
$215.30M
Mersana Therapeutics, Inc.
MRSN
$145.36M
OnKure Therapeutics, Inc.
NASDAQ:OKUR
$57.43M
Kezar Life Sciences, Inc.
KZR
$53.86M
FibroGen, Inc.
FGEN
$36.69M
INmune Bio, Inc.
INMB
$32.97M
Aligos Therapeutics, Inc.
ALGS
$32.67M
Skye Bioscience, Inc.
SKYE
$27.67M
Senti Biosciences, Inc.
SNTI
$25.24M
Tempest Therapeutics, Inc.
TPST
$5.60M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does XFOR generate?
X4 Pharmaceuticals, Inc. (XFOR) reported $35.11M of revenue in fiscal 2025.
Is XFOR profitable?
X4 Pharmaceuticals, Inc. (XFOR) reported -$79,199,000.00 of net income, with a net margin of -225.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.